Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
raeSd3hYwZXBDfPe
